The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.

J Pharm Policy Pract · 2016 · PMC5203724 · PMID 28050254

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

This variable is also slightly significant when NNRTI and “other” treatment regimen are compared, while PI/r and “other” treatment regimen do not differ significantly and can be considered as interchangeable.

also in 1,750 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.